Syntegon significantly increased its sales and earnings in the third quarter of 2025. The mechanical engineering company benefited in particular from strong demand from the pharmaceutical and biotech industries as well as efficiency programmes and high-margin technologies.
In the third quarter, the Group's total turnover rose by 19 per cent year-on-year to 448 million euros. Organic growth was 15 per cent. A key driver was the pharmaceutical business, which increased its sales by 32 per cent, 20 per cent of which was organic. Adjusted EBITDA increased by 37 per cent to 75 million euros in the same period, while the EBITDA margin improved to 16.7 per cent, an increase of 2.3 percentage points compared to the previous year.
Third quarter: momentum in the pharmaceutical business and new technologies
According to the company, Syntegon benefited from continued high customer demand, new project wins and the introduction of innovative line solutions in the pharmaceutical sector. Growth in the vial line business accelerated, also thanks to the integration of Telstar, which was acquired in 2024. As part of Syntegon, Telstar achieved a significant improvement in margins and strong growth in its core business with freeze dryers as well as a strong order intake in the area of prefilled RTU syringes.
The technological focal points include the syntiso fill/finish solution, which is positioned as the first gloveless, high-speed and isolator-integrated line solution in the industry. In the food segment, the modular, scalable svx platform contributed to growth and, according to the company, supported margin development. Syntegon thus sees itself as a strategic lifecycle partner for critical production and packaging solutions in the pharmaceutical, biotech and food industries.
Nine months 2025: Double-digit growth in sales, EBITDA and cash flow
In the first nine months of 2025, Syntegon generated total sales of 1.272 billion euros. This corresponds to an increase of 14 per cent compared to the previous year, of which 11 per cent was organic growth. Adjusted EBITDA rose by 40 per cent to EUR 202 million in the same period. The EBITDA margin improved to 15.9 per cent, up 3 percentage points on the previous year.
Free cash flow also developed positively, increasing by 31 per cent to 102 million euros in the first nine months. In this context, the company refers to consistent working capital management and targeted investments amounting to 2.6 per cent of sales.
Dealing with global risks and outlook for the year as a whole
Syntegon believes it is in a robust position despite geopolitical and trade policy uncertainties. The company expects potential negative effects from global trade developments - such as US tariffs - to be limited in 2025, partly due to a broadly diversified supply chain and close customer relationships. At the same time, the expansion of production capacities in the US pharmaceutical sector will open up additional business opportunities.
Syntegon expects another record year for 2025 as a whole in view of the strong growth, the continuous margin improvement and a record order backlog. The management emphasises that the company intends to consistently continue expanding its margins and further strengthen its financial base through solid cash flows and targeted investments in the future.
In the 2024 financial year, Syntegon achieved a turnover of 1.6 billion euros. According to its own information, the Group employs 6,900 people at 47 locations in more than 20 countries.
Source: Syntegon
